Ceramisys

What Ceramisys does

Ceramisys Ltd is a privately held medical device manufacturer founded in 2001 and headquartered in Sheffield, United Kingdom. The company specialises in the development and manufacture of synthetic, resorbable biomaterials for the repair and regeneration of bone, with a product portfolio centred on the ReproBone® range and additional lines branded ELIZ®, OSIQ®, and Repros®.

Its core technology is based on hydroxyapatite (HA) and beta-tricalcium phosphate (ß-TCP), engineered into multiphasic compositions with ultra-high porosity (above 80%) and high molecular surface area (~100 m²/g). The portfolio spans injectable pastes (ReproBone® fusion and novo), porous granules, and shapable blocks/wedges/cylinders/discs, indicated for filling bone defects in long bones, pelvis, extremities, and spinal fusion cages. Products are manufactured in-house at the Sheffield facility under ISO 13485 quality management certification (valid through July 2029, issued by BSi Netherlands).

Ceramisys operates a sales-led go-to-market model through a global network of authorized medical device distributors, with no direct sales force apparent from the data. It targets orthopaedic and trauma surgeons and the hospitals/surgical centres where they practise, generating revenue through one-time sale of medical device units. Pricing is not publicly disclosed and is handled via distributor quotation. Marketing is concentrated on major orthopaedic and spine congresses (EFORT, EuroSpine, BritSpine, BOA, Arab Health), and the website restricts product information behind a healthcare professional gate. The company is bootstrapped with no disclosed funding rounds, ownership structure, or revenue figures.

Name

Ceramisys

Legal name

Ceramisys Ltd

Website

https://ceramisys.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1–10 employees

Short description

Ceramisys Ltd is a Sheffield, UK-based medical device manufacturer founded in 2001 that produces synthetic, resorbable hydroxyapatite and beta-tricalcium phosphate bone grafts (ReproBone®, ELIZ®, OSIQ®, Repros®) for orthopaedic, trauma, and spinal fusion procedures, sold globally through authorized medical device distributors.

Ownership category

akta.pro rank

Product category

Orthopaedic Biomaterials

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Synthetic bone grafts
• Biomaterial manufacturing
• Orthopaedic medical devices
• Spinal fusion materials
• Hydroxyapatite implants

Headquarters

HQ city

Sheffield

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Others

Revenue model

1. Synthetic Bone Graft Products: Sale of proprietary synthetic bone graft products (ReproBone® product line) including fusion, novo, granules, and blocks. Products are medical devices sold to healthcare facilities and surgeons for bone repair and regeneration procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Ceramisys manufactures and sells proprietary synthetic, resorbable bone graft products under the ReproBone® brand, formulated from hydroxyapatite (HA) and beta-tricalcium phosphate (ß-TCP). The product range includes injectable pastes (ReproBone® fusion, ReproBone® novo), granules, and shaped blocks designed as osteoconductive and osteostimulative scaffolds for orthopaedic and trauma surgery, including spinal fusion procedures. Products are sold to healthcare facilities and surgeons through an authorized distributor network for use in bone defect repair and regeneration.

Product overview

Ceramisys is a medical device company manufacturing innovative synthetic biomaterials for bone repair and regeneration. The core product portfolio is the ReproBone® range, which includes four distinct synthetic resorbable bone graft formulations: ReproBone® fusion (injectable putty-like paste with micro-scaffolds), ReproBone® novo (injectable paste with nanotechnology-based hydroxyapatite), ReproBone® Granules (porous granules for bone defect filling), and ReproBone® Blocks (shapable blocks, wedges, cylinders and discs in various sizes). All ReproBone® products are composed of HA/ß-TCP (hydroxyapatite/beta-tricalcium phosphate) and are designed for orthopaedic and trauma surgery applications including spinal fusion procedures. The company also produces additional medical device products including ELIZ®, OSIQ®, and Repros®.

Differentiator

Problem solved

Functional benefit

Brands

• ReproBone®: Innovative range of synthetic, resorbable bone grafts that support bone integration and regeneration. Includes ReproBone® fusion (injectable matrix), ReproBone® novo (osteostimulative bone graft paste), ReproBone® Granules (resorbable synthetic bone graft granules), and ReproBone® Blocks (resorbable synthetic bone graft blocks with interconnected porous matrix).
• ELIZ®
• OSIQ®
• Repros®

Products and services

• ReproBone® fusion Synthetic bone graft product (injectable osteostimulative matrix) combining an osteostimulative carrier with porous micro-scaffolds, indicated for treating defects of long bones, pelvis and extremities and for filling of cages in spinal fusion procedures.
• ReproBone® novo Injectable osteostimulative bone graft paste with nanostructured high molecular surface area hydroxyapatite (~100 m²/g) for treating bone defects and spinal fusion procedures.
• ReproBone® Granules Resorbable synthetic bone graft granules with over 80% porosity and a highly interconnected porous matrix for treating defects of long bones, extremities, and interbody fusion of the spine.
• ReproBone® Blocks Resorbable synthetic bone graft blocks with over 80% porosity and highly interconnected porous matrix, available as blocks, wedges, cylinders, and discs in various sizes for shaping to fit bone defects.
• ELIZ® Medical device product from Ceramisys with available Instructions For Use and Patient Information Leaflet documentation.
• OSIQ® Medical device product from Ceramisys with available Instructions For Use and Patient Information Leaflet documentation.
• Repros® Medical device product from Ceramisys with available Instructions For Use and Patient Information Leaflet documentation.

Quantifiable outcome

• Over 80% porosity enabling rapid bone ingrowth
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Curasan AG: Curasan AG is a European orthobiologics specialist offering CERASORB synthetic beta-tricalcium phosphate bone graft materials for dental and orthopaedic use. Comparable to Ceramisys as a small, Europe-based specialist in synthetic calcium phosphate bone graft substitutes.

Direct peers

• Xtant Medical: Xtant Medical offers OrthoPure XT and OsteoSponge/ OsteoVive bone graft products for spinal and orthopaedic procedures. Comparable to Ceramisys as a smaller, specialised bone graft competitor addressing similar indications with synthetic and biologic grafts.
• Kuros Biosciences (MagnetOs): Kuros Biosciences markets MagnetOs bone graft, a synthetic calcium phosphate-based bone void filler with submicron topography for spinal and orthopaedic fusion. Closely comparable to Ceramisys as a focused synthetic bone graft specialist selling through distributors internationally.
• Cerapedics (i-FACTOR): Cerapedics is a small/mid-sized orthobiologics company whose i-FACTOR peptide-enhanced bone graft is FDA-approved for cervical spinal fusion. Closely comparable to Ceramisys as a specialty orthobiologics peer targeting spinal and orthopaedic fusion with a differentiated bone graft technology.

Broad incumbents

• Stryker (Vitoss, BIO4): Stryker offers Vitoss synthetic bone graft and the BIO4 viable bone matrix line, targeting orthopaedic and spinal fusion indications. Comparable to Ceramisys as a directly overlapping synthetic bone graft competitor, though operating as part of a much broader orthopaedics portfolio.
• Orthofix Medical (Trinity Evolution, fiberFUSE): Orthofix offers Trinity Evolution allograft and fiberFUSE synthetic bone graft products for spinal fusion and orthopaedic trauma. Comparable to Ceramisys as an orthobiologics competitor addressing similar bone regeneration indications, though with a broader spine and orthobiologics portfolio.
• Medtronic (Infuse / bone biologics): Medtronic is a global medical device incumbent with a bone biologics portfolio including Infuse (rhBMP-2) used in spinal fusion. It is comparable to Ceramisys as a competitor in the orthopaedic bone graft space, though at vastly greater scale and with biologic rather than purely synthetic technology.
• Bioventus (MagnetOS/BONISTINE/Signaling bone grafts): Bioventus markets bone graft solutions including OSTEOAMP and signaling-based bone graft substitutes for orthopaedic and spine surgery. Comparable to Ceramisys as a broader orthobiologics competitor in synthetic bone graft substitutes used in similar surgical indications.
• SeaSpine (now part of Globus Medical): SeaSpine (acquired by Globus Medical) sold OsteoStrand and OsteoSurge synthetic bone graft substitutes for spinal fusion. Comparable to Ceramisys as a direct competitor in synthetic bone grafts used in spinal fusion procedures, now part of a larger spine-focused incumbent.
• Baxter (Actifuse): Baxter's Actifuse is a synthetic bone graft substitute (silicate-substituted calcium phosphate) used in orthopaedic and spinal procedures. Directly comparable to Ceramisys' HA/β-TCP ReproBone line as a competing synthetic bone graft technology from a large diversified medical device company.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ceramisys